Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pituitary ACTH Hypersecretion | 40 | 2024 | 179 | 12.120 |
Why?
|
Human Growth Hormone | 68 | 2022 | 642 | 10.600 |
Why?
|
Cushing Syndrome | 35 | 2024 | 241 | 7.450 |
Why?
|
Acromegaly | 23 | 2020 | 310 | 3.730 |
Why?
|
Somatostatin | 19 | 2022 | 447 | 3.400 |
Why?
|
Hormone Replacement Therapy | 20 | 2021 | 751 | 3.110 |
Why?
|
Hydrocortisone | 41 | 2024 | 1819 | 2.960 |
Why?
|
Hypopituitarism | 17 | 2019 | 250 | 2.910 |
Why?
|
Dwarfism, Pituitary | 9 | 2022 | 39 | 2.530 |
Why?
|
Pituitary Neoplasms | 31 | 2023 | 1323 | 1.770 |
Why?
|
Adenoma | 21 | 2022 | 2163 | 1.680 |
Why?
|
Growth Hormone | 20 | 2022 | 569 | 1.630 |
Why?
|
Receptors, Somatotropin | 5 | 2020 | 58 | 1.590 |
Why?
|
Insulin-Like Growth Factor I | 35 | 2022 | 1935 | 1.470 |
Why?
|
Ketoconazole | 6 | 2021 | 97 | 1.440 |
Why?
|
Adrenocorticotropic Hormone | 20 | 2019 | 618 | 1.430 |
Why?
|
ACTH-Secreting Pituitary Adenoma | 5 | 2020 | 63 | 1.420 |
Why?
|
Dopamine Agonists | 10 | 2023 | 352 | 1.410 |
Why?
|
Adrenal Insufficiency | 10 | 2022 | 194 | 1.350 |
Why?
|
Hyperprolactinemia | 10 | 2023 | 124 | 1.310 |
Why?
|
Hormones | 7 | 2020 | 869 | 1.230 |
Why?
|
Pituitary Gland | 7 | 2021 | 635 | 1.070 |
Why?
|
Glucagon | 6 | 2016 | 532 | 1.030 |
Why?
|
Mifepristone | 6 | 2020 | 151 | 0.980 |
Why?
|
Receptors, Glucocorticoid | 3 | 2018 | 305 | 0.980 |
Why?
|
Endocrinology | 6 | 2020 | 442 | 0.950 |
Why?
|
Diagnostic Techniques, Endocrine | 3 | 2012 | 43 | 0.890 |
Why?
|
Hormone Antagonists | 6 | 2017 | 107 | 0.880 |
Why?
|
Imidazoles | 8 | 2024 | 1180 | 0.880 |
Why?
|
Quality of Life | 21 | 2024 | 13367 | 0.760 |
Why?
|
Bone Density | 14 | 2017 | 3551 | 0.740 |
Why?
|
Body Composition | 17 | 2020 | 2426 | 0.700 |
Why?
|
Arginine | 7 | 2020 | 934 | 0.650 |
Why?
|
Petrosal Sinus Sampling | 3 | 2012 | 22 | 0.640 |
Why?
|
Pituitary-Adrenal System | 5 | 2016 | 552 | 0.620 |
Why?
|
Adult | 133 | 2024 | 221210 | 0.600 |
Why?
|
Antimetabolites | 1 | 2018 | 129 | 0.580 |
Why?
|
Hypothalamo-Hypophyseal System | 5 | 2016 | 701 | 0.580 |
Why?
|
Circadian Rhythm | 5 | 2020 | 2576 | 0.580 |
Why?
|
Pyridines | 7 | 2024 | 2875 | 0.560 |
Why?
|
Corticotropin-Releasing Hormone | 7 | 2012 | 361 | 0.550 |
Why?
|
Prolactinoma | 5 | 2023 | 114 | 0.550 |
Why?
|
Recombinant Proteins | 8 | 2020 | 6534 | 0.550 |
Why?
|
Mitotane | 4 | 2020 | 20 | 0.530 |
Why?
|
Cranial Irradiation | 2 | 2017 | 390 | 0.520 |
Why?
|
Treatment Outcome | 37 | 2024 | 64685 | 0.510 |
Why?
|
Metyrapone | 4 | 2019 | 22 | 0.500 |
Why?
|
Humans | 186 | 2024 | 761596 | 0.470 |
Why?
|
Saliva | 7 | 2020 | 828 | 0.460 |
Why?
|
Steroid 11-beta-Hydroxylase | 1 | 2013 | 20 | 0.460 |
Why?
|
Neurotransmitter Agents | 1 | 2018 | 665 | 0.450 |
Why?
|
Middle Aged | 98 | 2024 | 220921 | 0.450 |
Why?
|
Female | 121 | 2024 | 392705 | 0.440 |
Why?
|
Radiosurgery | 6 | 2017 | 1342 | 0.440 |
Why?
|
Ergolines | 5 | 2017 | 57 | 0.430 |
Why?
|
Growth Disorders | 5 | 2019 | 655 | 0.400 |
Why?
|
Enzyme Inhibitors | 4 | 2022 | 3713 | 0.390 |
Why?
|
Male | 102 | 2024 | 360846 | 0.380 |
Why?
|
Prolactin | 8 | 2023 | 625 | 0.380 |
Why?
|
ACTH Syndrome, Ectopic | 2 | 2008 | 30 | 0.380 |
Why?
|
Heart Valves | 2 | 2010 | 284 | 0.370 |
Why?
|
Young Adult | 36 | 2024 | 59260 | 0.370 |
Why?
|
Adrenalectomy | 5 | 2017 | 346 | 0.360 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2018 | 1520 | 0.360 |
Why?
|
Consensus | 7 | 2021 | 3124 | 0.350 |
Why?
|
Databases, Factual | 9 | 2015 | 7968 | 0.340 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2020 | 10766 | 0.320 |
Why?
|
Amenorrhea | 7 | 1999 | 483 | 0.310 |
Why?
|
Societies, Scientific | 1 | 2009 | 222 | 0.310 |
Why?
|
Gonadal Steroid Hormones | 1 | 2011 | 702 | 0.280 |
Why?
|
Delayed-Action Preparations | 8 | 2018 | 962 | 0.280 |
Why?
|
Drug Administration Schedule | 8 | 2018 | 4853 | 0.270 |
Why?
|
Metabolism, Inborn Errors | 2 | 2007 | 284 | 0.260 |
Why?
|
Double-Blind Method | 16 | 2020 | 12341 | 0.260 |
Why?
|
Pituitary Diseases | 5 | 2016 | 135 | 0.260 |
Why?
|
Aged | 49 | 2024 | 169310 | 0.260 |
Why?
|
Lumbar Vertebrae | 2 | 2013 | 1879 | 0.250 |
Why?
|
Craniopharyngioma | 3 | 2017 | 276 | 0.240 |
Why?
|
Dexamethasone | 4 | 2009 | 1948 | 0.230 |
Why?
|
Pituitary Hormones, Anterior | 2 | 2022 | 56 | 0.230 |
Why?
|
Remission Induction | 6 | 2015 | 2397 | 0.230 |
Why?
|
Tryptophan | 2 | 2018 | 482 | 0.220 |
Why?
|
Etomidate | 2 | 2019 | 185 | 0.220 |
Why?
|
Retrospective Studies | 30 | 2021 | 80647 | 0.220 |
Why?
|
Neurosurgical Procedures | 4 | 2020 | 2072 | 0.220 |
Why?
|
Growth Hormone-Releasing Hormone | 4 | 2013 | 128 | 0.210 |
Why?
|
Insulin | 8 | 2022 | 6597 | 0.210 |
Why?
|
Bone Diseases, Metabolic | 5 | 1995 | 409 | 0.210 |
Why?
|
Reference Values | 7 | 2016 | 4920 | 0.210 |
Why?
|
Adipose Tissue | 5 | 2011 | 3313 | 0.200 |
Why?
|
Clinical Laboratory Techniques | 2 | 2020 | 746 | 0.200 |
Why?
|
Adolescent | 36 | 2023 | 88326 | 0.200 |
Why?
|
Heart Valve Diseases | 1 | 2010 | 1027 | 0.200 |
Why?
|
Hyperlipidemias | 2 | 2017 | 771 | 0.200 |
Why?
|
Age of Onset | 6 | 2018 | 3306 | 0.190 |
Why?
|
Octreotide | 5 | 2020 | 153 | 0.190 |
Why?
|
Leydig Cell Tumor | 1 | 2001 | 28 | 0.190 |
Why?
|
Mixed Function Oxygenases | 1 | 2022 | 265 | 0.190 |
Why?
|
Bone and Bones | 5 | 2009 | 2568 | 0.190 |
Why?
|
Follow-Up Studies | 12 | 2020 | 39106 | 0.180 |
Why?
|
Absorptiometry, Photon | 7 | 2017 | 1738 | 0.180 |
Why?
|
Cosyntropin | 2 | 2021 | 34 | 0.180 |
Why?
|
Gynecomastia | 1 | 2001 | 87 | 0.180 |
Why?
|
Blood Glucose | 11 | 2016 | 6391 | 0.180 |
Why?
|
Prospective Studies | 12 | 2024 | 54423 | 0.180 |
Why?
|
Body Mass Index | 10 | 2019 | 12953 | 0.180 |
Why?
|
Testosterone | 6 | 2022 | 2472 | 0.170 |
Why?
|
Internationality | 2 | 2018 | 1001 | 0.170 |
Why?
|
Body Height | 4 | 2018 | 1570 | 0.170 |
Why?
|
Insulin Resistance | 3 | 2012 | 3964 | 0.160 |
Why?
|
Hypoglycemic Agents | 4 | 2017 | 3085 | 0.160 |
Why?
|
Glucocorticoids | 2 | 2020 | 2161 | 0.160 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2021 | 258 | 0.160 |
Why?
|
Postoperative Care | 2 | 2005 | 1468 | 0.160 |
Why?
|
Pituitary Function Tests | 1 | 2018 | 24 | 0.160 |
Why?
|
Practice Guidelines as Topic | 5 | 2021 | 7391 | 0.160 |
Why?
|
Nelson Syndrome | 2 | 2008 | 20 | 0.150 |
Why?
|
Central Nervous System Cysts | 2 | 2016 | 56 | 0.150 |
Why?
|
Technology, Pharmaceutical | 1 | 2018 | 84 | 0.150 |
Why?
|
Waist Circumference | 2 | 2019 | 935 | 0.150 |
Why?
|
14-alpha Demethylase Inhibitors | 1 | 2017 | 4 | 0.150 |
Why?
|
Pituitary Irradiation | 1 | 2017 | 14 | 0.150 |
Why?
|
Medical Oncology | 1 | 2009 | 2321 | 0.150 |
Why?
|
Striae Distensae | 1 | 2017 | 7 | 0.150 |
Why?
|
Indoles | 2 | 2018 | 1833 | 0.150 |
Why?
|
Pregnancy Outcome | 2 | 2021 | 2922 | 0.150 |
Why?
|
Hypothalamic Diseases | 4 | 2012 | 134 | 0.150 |
Why?
|
Stimulation, Chemical | 2 | 2011 | 306 | 0.140 |
Why?
|
Hirsutism | 1 | 2017 | 68 | 0.140 |
Why?
|
Europe | 3 | 2019 | 3420 | 0.140 |
Why?
|
Sensitivity and Specificity | 7 | 2018 | 14665 | 0.140 |
Why?
|
Diagnostic Errors | 1 | 2004 | 1265 | 0.140 |
Why?
|
Alanine Transaminase | 1 | 2019 | 603 | 0.140 |
Why?
|
Child | 19 | 2023 | 80158 | 0.130 |
Why?
|
Age Factors | 7 | 2020 | 18399 | 0.130 |
Why?
|
Body Weight | 5 | 2016 | 4618 | 0.130 |
Why?
|
Adrenal Hyperplasia, Congenital | 1 | 2016 | 98 | 0.130 |
Why?
|
Hypertension | 5 | 2020 | 8540 | 0.130 |
Why?
|
Hypothalamus | 2 | 1991 | 999 | 0.130 |
Why?
|
Injections | 1 | 2018 | 831 | 0.120 |
Why?
|
Electric Impedance | 1 | 2019 | 757 | 0.120 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2000 | 625 | 0.120 |
Why?
|
Testicular Neoplasms | 1 | 2001 | 799 | 0.120 |
Why?
|
Long QT Syndrome | 1 | 2019 | 467 | 0.120 |
Why?
|
Radius | 2 | 2017 | 441 | 0.120 |
Why?
|
Sex Characteristics | 5 | 2011 | 2639 | 0.120 |
Why?
|
Cardiovascular Diseases | 11 | 2020 | 15502 | 0.120 |
Why?
|
Pituitary Apoplexy | 1 | 2014 | 29 | 0.120 |
Why?
|
Cholesterol | 3 | 2014 | 2905 | 0.120 |
Why?
|
Muscular Atrophy | 1 | 2017 | 334 | 0.120 |
Why?
|
Muscle Weakness | 1 | 2017 | 412 | 0.110 |
Why?
|
Thiazolidinediones | 1 | 2017 | 461 | 0.110 |
Why?
|
Obesity, Abdominal | 1 | 2017 | 374 | 0.110 |
Why?
|
Thyrotropin | 3 | 2014 | 834 | 0.110 |
Why?
|
Time Factors | 13 | 2020 | 39969 | 0.110 |
Why?
|
Radiotherapy | 1 | 2020 | 1498 | 0.110 |
Why?
|
Androgens | 3 | 2007 | 1286 | 0.110 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2017 | 376 | 0.100 |
Why?
|
Hospitals, General | 1 | 1997 | 798 | 0.100 |
Why?
|
United States | 8 | 2022 | 72340 | 0.100 |
Why?
|
Glucose Tolerance Test | 2 | 2017 | 1178 | 0.100 |
Why?
|
Diagnostic Tests, Routine | 1 | 2018 | 787 | 0.100 |
Why?
|
Patient Care Team | 2 | 2021 | 2521 | 0.100 |
Why?
|
Tetrahydronaphthalenes | 1 | 2012 | 86 | 0.100 |
Why?
|
Urinalysis | 1 | 2013 | 368 | 0.100 |
Why?
|
Sex Factors | 4 | 2013 | 10554 | 0.100 |
Why?
|
Impulsive Behavior | 1 | 2014 | 346 | 0.090 |
Why?
|
Femur Neck | 1 | 2013 | 314 | 0.090 |
Why?
|
Ghrelin | 1 | 2013 | 252 | 0.090 |
Why?
|
Tumor Burden | 1 | 2017 | 1892 | 0.090 |
Why?
|
Cysts | 1 | 2016 | 681 | 0.090 |
Why?
|
Ambulatory Care Facilities | 1 | 1997 | 935 | 0.090 |
Why?
|
Case-Control Studies | 5 | 2020 | 22176 | 0.090 |
Why?
|
Comorbidity | 4 | 2020 | 10508 | 0.090 |
Why?
|
Sella Turcica | 1 | 2010 | 118 | 0.090 |
Why?
|
Meningioma | 2 | 2017 | 1218 | 0.090 |
Why?
|
Pregnancy | 6 | 2023 | 29890 | 0.090 |
Why?
|
Cross-Sectional Studies | 8 | 2018 | 26129 | 0.090 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2015 | 732 | 0.080 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2015 | 1784 | 0.080 |
Why?
|
Adipokines | 1 | 2011 | 310 | 0.080 |
Why?
|
Neurology | 1 | 1997 | 780 | 0.080 |
Why?
|
Administration, Oral | 4 | 2020 | 4021 | 0.080 |
Why?
|
Perception | 1 | 2015 | 1197 | 0.080 |
Why?
|
Child Welfare | 1 | 2013 | 521 | 0.080 |
Why?
|
Insurance Coverage | 1 | 2000 | 1940 | 0.080 |
Why?
|
Diagnosis, Differential | 6 | 2010 | 12973 | 0.080 |
Why?
|
Neuroblastoma | 1 | 2017 | 1250 | 0.080 |
Why?
|
Pharmacoepidemiology | 1 | 2012 | 350 | 0.080 |
Why?
|
Nose | 1 | 2012 | 521 | 0.080 |
Why?
|
Mortality | 1 | 2020 | 2902 | 0.080 |
Why?
|
Needs Assessment | 1 | 2014 | 1139 | 0.080 |
Why?
|
Hypophysectomy | 1 | 2008 | 114 | 0.080 |
Why?
|
Knowledge | 1 | 2009 | 177 | 0.080 |
Why?
|
Prognosis | 5 | 2020 | 29629 | 0.080 |
Why?
|
Early Diagnosis | 1 | 2013 | 1186 | 0.080 |
Why?
|
Estrogens | 4 | 2022 | 1522 | 0.070 |
Why?
|
ROC Curve | 3 | 2020 | 3578 | 0.070 |
Why?
|
Statistics, Nonparametric | 2 | 2012 | 2850 | 0.070 |
Why?
|
Meningeal Neoplasms | 1 | 2017 | 1248 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 6312 | 0.070 |
Why?
|
Professional Practice | 1 | 2009 | 313 | 0.070 |
Why?
|
Blood Pressure | 3 | 2013 | 8481 | 0.070 |
Why?
|
Aged, 80 and over | 12 | 2018 | 58984 | 0.070 |
Why?
|
Cross-Over Studies | 4 | 2018 | 2079 | 0.070 |
Why?
|
Endocrine System Diseases | 2 | 2002 | 249 | 0.070 |
Why?
|
Bromocriptine | 3 | 2007 | 93 | 0.070 |
Why?
|
Single-Blind Method | 4 | 2012 | 1574 | 0.070 |
Why?
|
Anorexia Nervosa | 3 | 1995 | 1361 | 0.070 |
Why?
|
Steroid Metabolism, Inborn Errors | 1 | 2005 | 5 | 0.070 |
Why?
|
Recurrence | 7 | 2015 | 8466 | 0.060 |
Why?
|
Spine | 3 | 2011 | 1118 | 0.060 |
Why?
|
Bariatric Surgery | 1 | 2015 | 992 | 0.060 |
Why?
|
Homeostasis | 1 | 2016 | 3323 | 0.060 |
Why?
|
Quinazolines | 1 | 2012 | 1371 | 0.060 |
Why?
|
Triglycerides | 1 | 2013 | 2461 | 0.060 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 3808 | 0.060 |
Why?
|
Injections, Subcutaneous | 2 | 2022 | 681 | 0.060 |
Why?
|
Drug Interactions | 1 | 2009 | 1416 | 0.060 |
Why?
|
Differential Threshold | 1 | 2004 | 80 | 0.060 |
Why?
|
Obesity, Morbid | 1 | 2015 | 1277 | 0.060 |
Why?
|
Levodopa | 2 | 2002 | 221 | 0.060 |
Why?
|
Deficiency Diseases | 1 | 2004 | 74 | 0.060 |
Why?
|
Estradiol | 3 | 2001 | 1937 | 0.060 |
Why?
|
Longitudinal Studies | 3 | 2010 | 14608 | 0.060 |
Why?
|
Analysis of Variance | 2 | 2011 | 6228 | 0.060 |
Why?
|
Risk Factors | 12 | 2020 | 74213 | 0.060 |
Why?
|
Pituitary Hormones | 2 | 2021 | 182 | 0.060 |
Why?
|
Societies, Medical | 1 | 2015 | 3905 | 0.050 |
Why?
|
Overweight | 1 | 2014 | 2417 | 0.050 |
Why?
|
False Negative Reactions | 1 | 2004 | 573 | 0.050 |
Why?
|
International Cooperation | 1 | 2009 | 1422 | 0.050 |
Why?
|
Oligopeptides | 1 | 2008 | 1187 | 0.050 |
Why?
|
Intra-Abdominal Fat | 1 | 2008 | 613 | 0.050 |
Why?
|
Feasibility Studies | 1 | 2013 | 5247 | 0.050 |
Why?
|
Chemistry, Pharmaceutical | 2 | 2015 | 274 | 0.050 |
Why?
|
Osteoporosis | 2 | 2009 | 1606 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
Phenol | 1 | 2022 | 44 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
Models, Theoretical | 1 | 2014 | 3575 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2022 | 9280 | 0.050 |
Why?
|
Radiography | 1 | 2013 | 6965 | 0.050 |
Why?
|
Glioma | 1 | 2017 | 3455 | 0.050 |
Why?
|
Logistic Models | 1 | 2016 | 13255 | 0.050 |
Why?
|
Mannitol | 1 | 2022 | 180 | 0.050 |
Why?
|
Homocystine | 1 | 2001 | 21 | 0.050 |
Why?
|
Anxiety | 1 | 2016 | 4573 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2020 | 6484 | 0.050 |
Why?
|
Histidine | 1 | 2022 | 308 | 0.050 |
Why?
|
Diabetes Mellitus | 2 | 2016 | 5841 | 0.050 |
Why?
|
Hepatitis C Antibodies | 1 | 2001 | 146 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 2019 | 20100 | 0.050 |
Why?
|
Child, Preschool | 5 | 2018 | 42232 | 0.050 |
Why?
|
Hospitalization | 2 | 2021 | 10721 | 0.050 |
Why?
|
Postoperative Period | 2 | 2015 | 1814 | 0.040 |
Why?
|
Heroin Dependence | 1 | 2001 | 172 | 0.040 |
Why?
|
Sphenoid Bone | 2 | 2014 | 177 | 0.040 |
Why?
|
Galactorrhea | 1 | 1999 | 23 | 0.040 |
Why?
|
Lipids | 6 | 2012 | 3341 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 8 | 2016 | 36426 | 0.040 |
Why?
|
Receptors, Somatostatin | 1 | 2020 | 136 | 0.040 |
Why?
|
Severity of Illness Index | 3 | 2013 | 15843 | 0.040 |
Why?
|
Orchiectomy | 1 | 2001 | 463 | 0.040 |
Why?
|
Placebos | 4 | 2008 | 1667 | 0.040 |
Why?
|
Fractures, Bone | 1 | 2011 | 2046 | 0.040 |
Why?
|
Abdomen | 1 | 2004 | 1128 | 0.040 |
Why?
|
Testis | 1 | 2001 | 794 | 0.040 |
Why?
|
Homocysteine | 1 | 2001 | 638 | 0.040 |
Why?
|
Time | 1 | 2019 | 546 | 0.040 |
Why?
|
Animals | 4 | 2020 | 168475 | 0.040 |
Why?
|
Endocrine Glands | 1 | 1997 | 102 | 0.040 |
Why?
|
Fasting | 2 | 2019 | 1603 | 0.030 |
Why?
|
HIV Wasting Syndrome | 1 | 1997 | 99 | 0.030 |
Why?
|
Health Status | 1 | 2010 | 4077 | 0.030 |
Why?
|
Depression | 1 | 2016 | 8126 | 0.030 |
Why?
|
Evidence-Based Medicine | 3 | 2015 | 3688 | 0.030 |
Why?
|
Gonads | 1 | 1996 | 109 | 0.030 |
Why?
|
Antineoplastic Agents | 2 | 2017 | 13642 | 0.030 |
Why?
|
Drug Combinations | 1 | 2002 | 2048 | 0.030 |
Why?
|
Medical History Taking | 1 | 1999 | 774 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2017 | 504 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2017 | 9032 | 0.030 |
Why?
|
Lipoproteins | 2 | 2012 | 881 | 0.030 |
Why?
|
Metabolic Diseases | 1 | 2002 | 683 | 0.030 |
Why?
|
Oligodendroglioma | 1 | 2017 | 279 | 0.030 |
Why?
|
Glucose | 2 | 2022 | 4347 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2020 | 1380 | 0.030 |
Why?
|
Managed Care Programs | 1 | 2000 | 940 | 0.030 |
Why?
|
Blotting, Southern | 2 | 1992 | 777 | 0.030 |
Why?
|
Obesity | 2 | 2014 | 12947 | 0.030 |
Why?
|
Regression Analysis | 3 | 2017 | 6345 | 0.030 |
Why?
|
Progesterone | 1 | 1999 | 742 | 0.030 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 1992 | 767 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2014 | 166 | 0.030 |
Why?
|
Immune System Diseases | 1 | 2016 | 256 | 0.030 |
Why?
|
Follicle Stimulating Hormone | 3 | 1995 | 726 | 0.030 |
Why?
|
Infertility, Female | 1 | 1999 | 760 | 0.030 |
Why?
|
Luteinizing Hormone | 3 | 1995 | 820 | 0.030 |
Why?
|
Gonadotropin-Releasing Hormone | 2 | 1990 | 1148 | 0.030 |
Why?
|
Ultrasonography | 2 | 2009 | 5971 | 0.030 |
Why?
|
Safety | 1 | 2017 | 1149 | 0.030 |
Why?
|
Cohort Studies | 2 | 2020 | 41495 | 0.030 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2016 | 357 | 0.030 |
Why?
|
Education | 1 | 2015 | 537 | 0.030 |
Why?
|
Diagnostic Imaging | 2 | 2023 | 3530 | 0.030 |
Why?
|
Astrocytoma | 1 | 2017 | 775 | 0.030 |
Why?
|
Glasgow Coma Scale | 1 | 2014 | 580 | 0.030 |
Why?
|
Clone Cells | 2 | 1992 | 1659 | 0.020 |
Why?
|
Massachusetts | 2 | 2012 | 8833 | 0.020 |
Why?
|
Live Birth | 1 | 2015 | 511 | 0.020 |
Why?
|
Osmolar Concentration | 1 | 1992 | 659 | 0.020 |
Why?
|
Survivors | 1 | 2022 | 2371 | 0.020 |
Why?
|
Puberty, Delayed | 1 | 1992 | 121 | 0.020 |
Why?
|
Radiotherapy, Conformal | 1 | 2014 | 548 | 0.020 |
Why?
|
Lipoproteins, LDL | 1 | 2014 | 642 | 0.020 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2015 | 497 | 0.020 |
Why?
|
Liver Function Tests | 1 | 2012 | 523 | 0.020 |
Why?
|
Aging | 3 | 2002 | 8710 | 0.020 |
Why?
|
Aftercare | 1 | 2016 | 914 | 0.020 |
Why?
|
Musculoskeletal Diseases | 1 | 2016 | 598 | 0.020 |
Why?
|
Aminoquinolines | 1 | 1990 | 107 | 0.020 |
Why?
|
Patient Care Planning | 1 | 2015 | 909 | 0.020 |
Why?
|
Urea | 1 | 2012 | 443 | 0.020 |
Why?
|
C-Reactive Protein | 3 | 2010 | 3826 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2643 | 0.020 |
Why?
|
Survival Rate | 2 | 2020 | 12723 | 0.020 |
Why?
|
Cause of Death | 1 | 2020 | 3683 | 0.020 |
Why?
|
Visual Fields | 1 | 1996 | 1062 | 0.020 |
Why?
|
Dopamine Agents | 1 | 1990 | 189 | 0.020 |
Why?
|
Doping in Sports | 1 | 2009 | 62 | 0.020 |
Why?
|
X Chromosome | 1 | 1992 | 816 | 0.020 |
Why?
|
Research | 1 | 1997 | 1982 | 0.020 |
Why?
|
Somatomedins | 1 | 1989 | 179 | 0.020 |
Why?
|
Postoperative Complications | 3 | 2008 | 15633 | 0.020 |
Why?
|
Gallbladder | 1 | 2009 | 308 | 0.020 |
Why?
|
Glucose Intolerance | 1 | 2012 | 575 | 0.020 |
Why?
|
Minerals | 1 | 1989 | 283 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 2 | 2002 | 416 | 0.020 |
Why?
|
Ependymoma | 1 | 2010 | 320 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2014 | 2898 | 0.020 |
Why?
|
Anthropometry | 2 | 2004 | 1349 | 0.020 |
Why?
|
Growth Hormone-Secreting Pituitary Adenoma | 1 | 2007 | 49 | 0.020 |
Why?
|
Calcitriol | 1 | 1989 | 296 | 0.020 |
Why?
|
Area Under Curve | 1 | 2011 | 1638 | 0.020 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2012 | 452 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2010 | 590 | 0.020 |
Why?
|
Birth Weight | 1 | 2015 | 2103 | 0.020 |
Why?
|
Health Services Research | 1 | 2014 | 1812 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 1997 | 1667 | 0.020 |
Why?
|
Quinolines | 1 | 2012 | 765 | 0.020 |
Why?
|
Gestational Age | 1 | 2015 | 3577 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 4 | 2005 | 20568 | 0.020 |
Why?
|
Cognition | 2 | 2006 | 6992 | 0.020 |
Why?
|
Bone Resorption | 1 | 1989 | 723 | 0.020 |
Why?
|
Menstrual Cycle | 3 | 1999 | 539 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1779 | 0.020 |
Why?
|
Weight Gain | 1 | 2015 | 2348 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12463 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 1997 | 2373 | 0.020 |
Why?
|
Inpatients | 1 | 2016 | 2548 | 0.010 |
Why?
|
Metabolome | 1 | 2011 | 989 | 0.010 |
Why?
|
Smoking | 1 | 2001 | 9053 | 0.010 |
Why?
|
Psychometrics | 1 | 2014 | 3065 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2012 | 1886 | 0.010 |
Why?
|
Infant | 2 | 2018 | 36193 | 0.010 |
Why?
|
Leptin | 1 | 2011 | 1597 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1992 | 6075 | 0.010 |
Why?
|
Mental Disorders | 2 | 2016 | 6845 | 0.010 |
Why?
|
Clinical Chemistry Tests | 1 | 2003 | 59 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2009 | 1386 | 0.010 |
Why?
|
Self Report | 1 | 2014 | 3725 | 0.010 |
Why?
|
Prevalence | 2 | 2014 | 15733 | 0.010 |
Why?
|
Stress, Physiological | 1 | 1990 | 1403 | 0.010 |
Why?
|
Antihypertensive Agents | 1 | 2012 | 2024 | 0.010 |
Why?
|
Protons | 1 | 2007 | 1116 | 0.010 |
Why?
|
Glioblastoma | 1 | 2017 | 3483 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2012 | 6019 | 0.010 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 15266 | 0.010 |
Why?
|
Physical Endurance | 1 | 2004 | 366 | 0.010 |
Why?
|
Pregnancy Complications | 1 | 2015 | 2947 | 0.010 |
Why?
|
Menopause | 1 | 1989 | 1646 | 0.010 |
Why?
|
Pheochromocytoma | 1 | 2003 | 328 | 0.010 |
Why?
|
Biopsy | 1 | 1992 | 6766 | 0.010 |
Why?
|
Pilot Projects | 1 | 2014 | 8633 | 0.010 |
Why?
|
Inflammation | 1 | 2000 | 10774 | 0.010 |
Why?
|
Pediatrics | 1 | 2015 | 3589 | 0.010 |
Why?
|
Serum Amyloid A Protein | 1 | 2000 | 127 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8656 | 0.010 |
Why?
|
Arousal | 1 | 2006 | 1166 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 6180 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 8002 | 0.010 |
Why?
|
Hypogonadism | 1 | 2006 | 798 | 0.010 |
Why?
|
Calcitonin | 1 | 1980 | 329 | 0.010 |
Why?
|
Administration, Intravaginal | 1 | 1999 | 150 | 0.010 |
Why?
|
Matched-Pair Analysis | 1 | 1999 | 284 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2007 | 1902 | 0.010 |
Why?
|
Incidence | 1 | 2017 | 21355 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 1993 | 5799 | 0.010 |
Why?
|
Weight Loss | 1 | 1990 | 2684 | 0.010 |
Why?
|
Primary Ovarian Insufficiency | 1 | 1999 | 107 | 0.010 |
Why?
|
Child Development | 1 | 2010 | 2306 | 0.010 |
Why?
|
Thyroid Hormones | 1 | 2001 | 404 | 0.010 |
Why?
|
Affect | 1 | 2006 | 1486 | 0.010 |
Why?
|
Vitamin B 12 | 1 | 2001 | 524 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2003 | 1626 | 0.010 |
Why?
|
Nutrition Assessment | 1 | 2001 | 728 | 0.010 |
Why?
|
Gels | 1 | 1999 | 420 | 0.010 |
Why?
|
Kinetics | 2 | 2002 | 6374 | 0.010 |
Why?
|
Reoperation | 1 | 2008 | 4303 | 0.010 |
Why?
|
Emotions | 1 | 2009 | 2739 | 0.010 |
Why?
|
Echocardiography | 1 | 2009 | 4989 | 0.010 |
Why?
|
Carrier Proteins | 2 | 2002 | 4937 | 0.010 |
Why?
|
Dehydroepiandrosterone Sulfate | 1 | 1997 | 241 | 0.010 |
Why?
|
Endometrium | 1 | 1999 | 403 | 0.010 |
Why?
|
Sexual Behavior | 1 | 2006 | 2180 | 0.010 |
Why?
|
Insulin-Like Growth Factor Binding Protein 2 | 1 | 1996 | 68 | 0.010 |
Why?
|
Muscle, Skeletal | 2 | 2004 | 4948 | 0.010 |
Why?
|
Glycoproteins | 1 | 2002 | 2203 | 0.010 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 1997 | 550 | 0.010 |
Why?
|
Folic Acid | 1 | 2001 | 1323 | 0.010 |
Why?
|
Seizures | 1 | 1987 | 2957 | 0.010 |
Why?
|
Morbidity | 1 | 1998 | 1752 | 0.010 |
Why?
|
Statistics as Topic | 1 | 1999 | 2358 | 0.010 |
Why?
|
Ion Exchange | 1 | 1972 | 16 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2009 | 10212 | 0.010 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 1993 | 283 | 0.010 |
Why?
|
Muscles | 1 | 1997 | 1576 | 0.010 |
Why?
|
Risk Assessment | 1 | 2013 | 23996 | 0.010 |
Why?
|
Amphetamine | 1 | 1972 | 224 | 0.010 |
Why?
|
Phosphoglycerate Kinase | 1 | 1990 | 66 | 0.010 |
Why?
|
Hypoxanthine Phosphoribosyltransferase | 1 | 1990 | 69 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2000 | 3208 | 0.010 |
Why?
|
Narcotics | 1 | 1972 | 336 | 0.010 |
Why?
|
Libido | 1 | 1990 | 119 | 0.010 |
Why?
|
Energy Intake | 1 | 1997 | 2134 | 0.010 |
Why?
|
Dosage Compensation, Genetic | 1 | 1990 | 207 | 0.010 |
Why?
|
Carcinoma | 1 | 1980 | 2330 | 0.010 |
Why?
|
Disabled Persons | 1 | 1998 | 1226 | 0.000 |
Why?
|
Nutritional Status | 1 | 1997 | 1615 | 0.000 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2012 | 12149 | 0.000 |
Why?
|
Methylation | 1 | 1990 | 1084 | 0.000 |
Why?
|
Thyroid Neoplasms | 1 | 1980 | 2332 | 0.000 |
Why?
|
Erectile Dysfunction | 1 | 1990 | 444 | 0.000 |
Why?
|
Combined Modality Therapy | 1 | 1998 | 8527 | 0.000 |
Why?
|
Menarche | 1 | 1989 | 532 | 0.000 |
Why?
|
Energy Metabolism | 1 | 1997 | 2882 | 0.000 |
Why?
|
Hypnotics and Sedatives | 1 | 1972 | 1179 | 0.000 |
Why?
|
Chronic Disease | 1 | 1998 | 9319 | 0.000 |
Why?
|
Pentagastrin | 1 | 1980 | 17 | 0.000 |
Why?
|
Neoplasms | 1 | 2010 | 22173 | 0.000 |
Why?
|
Exercise | 1 | 1996 | 5890 | 0.000 |
Why?
|
Substance-Related Disorders | 1 | 1972 | 4420 | 0.000 |
Why?
|
Chromatography, Thin Layer | 1 | 1972 | 213 | 0.000 |
Why?
|
Methods | 1 | 1972 | 1067 | 0.000 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1972 | 2496 | 0.000 |
Why?
|